[6R]-MTHF Folate Regimen for Consistent 5-FU Chemotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 5-fluorouracil (5-FU) based chemotherapy protocols for treating solid tumors, such as colorectal cancer, achieve limited response rates due to interindividual metabolic variability and the need for metabolic activation of folate enhancers like leucovorin, leading to suboptimal therapeutic outcomes.
Innovation Solution
Administering [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF) in combination with 5-FU through a specific regimen involving initial 5-FU bolus followed by multiple IV boluses of [6R]-MTHF, interspaced by intervals, and a continuous infusion, to directly form the FdUMP-Thymidylate Synthase complex without requiring metabolic conversion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If leucovorin is used as a folate enhancer in 5-FU based chemotherapy, then the anticancer activity is modulated and response rates increase, but metabolic activation is required which leads to interindividual variability and suboptimal therapeutic outcomes
Solution Approach 1:
The patent uses [6R]-MTHF, which is already in the active form and does not require metabolic activation. This preliminary preparation of the active metabolite eliminates the variability introduced by requiring cellular conversion of leucovorin, directly resolving the contradiction between therapeutic reliability and metabolic complexity.
Solution Approach 2:
The patent extracts the metabolic activation step from the treatment protocol by using pre-activated [6R]-MTHF instead of leucovorin. This removes the source of interindividual variability in metabolic conversion, improving therapeutic outcome reliability without requiring complex metabolic processing.
2Productivity
If standard 5-FU based protocols are used, then treatment is administered, but response rates are limited to 10-15% without folate enhancement
Solution Approach 1:
The patent changes the chemical form of the folate from leucovorin (requiring activation) to [6R]-MTHF (already active), and specifies precise dosing parameters (5-1000 mg/m2 BSA in multiple boluses). This parameter change transforms the treatment from limited response (10-15%) to superior response rates (50-60%), improving both productivity and therapeutic consistency.
3Reliability
If multiple boluses of [6R]-MTHF are administered interspaced by intervals, then direct complex formation is achieved, but administration complexity increases
Solution Approach 1:
The patent segments the [6R]-MTHF administration into multiple boluses (1-4 times per day) with specific intervals. This segmentation allows direct complex formation with FdUMP and Thymidylate Synthase while managing administration complexity through a structured, repeatable protocol that can be efficiently implemented in clinical settings.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves objective response rates of 50-60% and significant tumor reduction in treated patients, with over 90% experiencing stable disease or tumor response, surpassing previous protocols.
Implementation Method 1
This ternary complex inhibits the enzyme thymidylate synthase, an enzyme necessary for DNA synthesis
Data Source
AI summary
The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering the diastereomerically pure folate adjuvant [6R]-5, 10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.